Acute Leukemia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ACT073 MIFTS: 60	Acute Leukemia Categories: Cancer diseases, Immune diseases, Blood diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Acute Leukemia

MalaCards integrated aliases for Acute Leukemia:

Name: Acute Leukemia ³⁸ ¹² ²⁹ ⁵⁵ ¹⁵ ⁷³

Acute Undifferentiated Leukemia ⁷³

Undifferentiated Leukemia ⁷³

Stem Cell Leukaemia ¹²

Stem Cell Leukemia ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Immune diseases Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Leukaemia of unspecified cell type

Acute leukaemia of unspecified cell type

External Ids:

Disease Ontology ¹² DOID:12603

ICD10 ³³ C95.0 C95.00

ICD9CM ³⁵ 208.0

NCIt ⁵⁰ C9298 C9300

SNOMED-CT ⁶⁸ 154599000 188763007 24072005 more

UMLS ⁷³ C0085669 C1378511 C0280141

Sources

Summaries for Acute Leukemia

Disease Ontology : ¹² A leukemia that occurs when a hematopoietic stem cell undergoes malignant transformation into a primitive, undifferentiated cell with abnormal longevity. These lymphocytes (acute lymphocytic leukemia [ALL]) or myeloid cells (acute myelocytic leukemia [AML]) proliferate abnormally, replacing normal marrow tissue and hematopoietic cells and inducing anemia, thrombocytopenia, and granulocytopenia.

MalaCards based summary : Acute Leukemia, also known as acute undifferentiated leukemia, is related to chronic eosinophilic leukemia and leukemia, acute lymphoblastic. An important gene associated with Acute Leukemia is BAALC (BAALC, MAP3K1 And KLF4 Binding), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Busulfex and Clolar have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Wikipedia : ⁷⁶ Acute leukemia or acute leukaemia is a family of serious medical conditions relating to an original... more...

Sources

Related Diseases for Acute Leukemia

Diseases in the Leukemia family:

Acute Leukemia	Chronic Leukemia
Subacute Leukemia

Diseases related to Acute Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 290)

#	Related Disease	Score	Top Affiliating Genes
1	chronic eosinophilic leukemia	33.0	FLT3 KIT WT1
2	leukemia, acute lymphoblastic	32.8	AFF1 DNTT ETV6 FLT3 KMT2A RUNX1
3	childhood leukemia	32.5	ETV6 KMT2A MLLT1 MTHFR RUNX1
4	acute lymphocytic leukemia	32.3	CSF3 ETV6 GSTM1 MTHFR RUNX1
5	lymphoblastic lymphoma	32.2	DNTT KMT2A MPO
6	leukemia	32.0	BAALC CEBPA ETV6 FLT3 JAK2 KIT
7	acute promyelocytic leukemia	30.6	ANPEP CD34 CEBPA CSF3 FLT3 MPO
8	lymphoid leukemia	30.6	ETV6 FLT3 JAK2 KMT2A
9	lymphoblastic leukemia	30.6	AFF1 ETV6 FLT3 JAK2 MLLT1 RUNX1
10	8p11 myeloproliferative syndrome	30.4	FLT3 KIT RUNX1
11	megakaryocytic leukemia	30.4	JAK2 MPO RUNX1
12	chronic myelomonocytic leukemia	30.3	ETV6 FLT3 JAK2 KIT RUNX1
13	cytogenetically normal acute myeloid leukemia	30.1	CEBPA FLT3 KMT2A WT1
14	myeloid leukemia	29.7	CEBPA CREBBP ETV6 FLT3 JAK2 KIT
15	aplastic anemia	29.0	CD34 CSF3 FLT3 GSTM1
16	myelofibrosis	28.9	CD34 CSF3 FLT3 JAK2 KIT
17	myeloid sarcoma	28.8	ANPEP DNTT FLT3 KIT KMT2A MPO
18	leukemia, acute myeloid	27.9	AFF1 ANPEP BAALC CD34 CEBPA CSF3
19	acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)	27.8	CREBBP DNTT ETV6 FLT3 KIT KMT2A
20	myelodysplastic syndrome	27.7	ANPEP CD34 CEBPA CREBBP CSF3 DNTT
21	leukemia, chronic myeloid	26.7	CD34 CSF3 DNTT ETV6 FLT3 JAK2
22	acute leukemia of ambiguous lineage	12.2
23	chromosome 8p11 myeloproliferative syndrome	11.7
24	invasive aspergillosis	11.2
25	myeloproliferative neoplasm	11.2
26	ring chromosome 21	11.0	ETV6 KMT2A
27	acute myeloblastic leukemia with maturation	11.0	FLT3 KIT
28	platelet disorder, familial, with associated myeloid malignancy	11.0	ETV6 RUNX1
29	testicular gonadoblastoma	11.0	KIT WT1
30	b-cell childhood acute lymphoblastic leukemia	10.9	ETV6 RUNX1
31	mn1	10.9	ETV6 FLT3 KMT2A
32	myelodysplastic myeloproliferative cancer	10.9
33	chronic leukemia	10.9
34	mthfr gene variant	10.9
35	acute myeloid leukemia with minimal differentiation	10.8	FLT3 MPO
36	nondisjunction	10.8	KIT MTHFR
37	blood coagulation disease	10.8	CSF3 JAK2 MTHFR
38	congenital mesoblastic nephroma	10.8	ETV6 KIT WT1
39	neutrophilia, hereditary	10.8	FLT3 JAK2
40	neonatal leukemia	10.7	AFF1 CREBBP FLT3
41	malignant mesenchymoma	10.7	ETV6 KIT WT1
42	blood platelet disease	10.7	CSF3 JAK2 RUNX1
43	myelophthisic anemia	10.7	ANPEP JAK2
44	acute lymphoblastic leukemia, childhood	10.7	ETV6 GSTM1 MTHFR RUNX1
45	acute basophilic leukemia	10.6	ETV6 MPO
46	arteritic anterior ischemic optic neuropathy	10.6	GSTM1 MPO MTHFR
47	acute myeloid leukemia with t(8;21)(q22;q22) translocation	10.6	CEBPA FLT3 KIT RUNX1
48	severe congenital neutropenia	10.6	CSF3 JAK2 RUNX1
49	leukemia, acute monocytic	10.5	CREBBP KMT2A MPO
50	gallbladder leiomyoma	10.5	CD34 KIT

Comorbidity relations with Acute Leukemia via Phenotypic Disease Network (PDN):

Deficiency Anemia

Neutropenia

Graphical network of the top 20 diseases related to Acute Leukemia:

Sources

Symptoms & Phenotypes for Acute Leukemia

GenomeRNAi Phenotypes related to Acute Leukemia according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.17	CD34 CEBPA CSF3 ETV6 GSTM1 KMT2A

MGI Mouse Phenotypes related to Acute Leukemia:

⁴⁶ (show all 13)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system	MP:0005397	10.38	FLT3 JAK2 KIT KMT2A MLLT1 MPO
2	immune system	MP:0005387	10.34	AFF1 ANPEP CD34 CEBPA CREBBP CSF3
3	homeostasis/metabolism	MP:0005376	10.3	CD34 CEBPA CREBBP DNTT ETV6 FLT3
4	cardiovascular system	MP:0005385	10.26	ANPEP CEBPA CREBBP DNTT ETV6 KIT
5	growth/size/body region	MP:0005378	10.24	AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
6	endocrine/exocrine gland	MP:0005379	10.21	AFF1 ANPEP CEBPA CREBBP ETV6 FLT3
7	integument	MP:0010771	10.14	ANPEP CD34 CEBPA CREBBP CSF3 ETV6
8	mortality/aging	MP:0010768	10.13	MTHFR RUNX1 WT1 AFF1 CEBPA CREBBP
9	liver/biliary system	MP:0005370	9.97	CEBPA CREBBP JAK2 KIT KMT2A MLLT1
10	neoplasm	MP:0002006	9.9	JAK2 KIT KMT2A MLLT1 RUNX1 WT1
11	muscle	MP:0005369	9.8	CEBPA CREBBP KIT KMT2A MPO STMN1
12	no phenotypic analysis	MP:0003012	9.61	KMT2A MTHFR RUNX1 WT1 AFF1 CEBPA
13	normal	MP:0002873	9.36	DNTT ETV6 JAK2 KIT KMT2A MLLT1

Sources

Drugs & Therapeutics for Acute Leukemia

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Busulfex ¹⁸ ⁴⁹	BUSULFAN	Orphan Medical	February 1999
FDA Label: Busulfex Disease/s that Drug Treats:leukemia Indications and Usage: ¹⁸ BUSULFEX is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimenprior to allogeneic hematopoietic progenitor cell transplantation forchronic myelogenous leukemia (CML) (1) DrugBank Targets: ¹⁶ DNA Mechanism of Action: ¹⁸ Target: DNA Action: alkylyzer FDA: Busulfan is a bifunctional alkylating agent in which two labile methanesulfonate groups are attached to opposite ends of afour-carbon alkyl chain. In aqueous media, busulfan hydrolyzes to release the methanesulfonate groups. This producesreactive carbonium ions that can alkylate DNA. DNA damage is thought to be responsible for much of the cytotoxicity ofbusulfan.
2	Clolar ¹⁸ ⁴⁹	CLOFARABINE	Genzyme	December, 2004
FDA Label: Clolar Disease/s that Drug Treats:Lymphoblastic Leukemia Indications and Usage: ¹⁸ Clolar (clofarabine) injection is a purine nucleoside metabolic inhibitorindicated for the treatment of pediatric patients 1 to 21 years old with relapsedor refractory acute lymphoblastic leukemia after at least two prior regimens.This indication is based upon response rate. There are no trials verifying animprovement in disease-related symptoms or increased survival with Clolar.(1) DrugBank Targets: ¹⁶ 1. DNA polymerase alpha catalytic subunit;2. Ribonucleoside-diphosphate reductase large subunit;3. DNA Mechanism of Action: ¹⁸ Target: ribonucleotide reductase Action: inhibitor FDA: Clofarabine is sequentially metabolized intracellularly to the 5â-monophosphate metabolite bydeoxycytidine kinase and mono- and di-phospho-kinases to the active 5â-triphosphate metabolite.Clofarabine has affinity for the activating phosphorylating enzyme, deoxycytidine kinase, equalto or greater than that of the natural substrate, deoxycytidine. Clofarabine inhibits DNA synthesisby decreasing cellular deoxynucleotide triphosphate pools through an inhibitory action onribonucleotide reductase, and by terminating DNA chain elongation and inhibiting repair throughincorporation into the DNA chain by competitive inhibition of DNA polymerases. The affinity ofclofarabine triphosphate for these enzymes is similar to or greater than that of deoxyadenosinetriphosphate. In preclinical models, clofarabine has demonstrated the ability to inhibit DNArepair by incorporation into the DNA chain during the repair process. Clofarabine 5â-triphosphate also disrupts the integrity of mitochondrial membrane, leading to the release of thepro-apoptotic mitochondrial proteins, cytochrome C and apoptosis-inducing factor, leading toprogrammed cell death.Clofarabine is cytotoxic to rapidly proliferating and quiescent cancer cell types in vitro.
3	Marqibo ¹⁸ ⁴⁹	VINCRISTINE SULFATE	Talon Therapeutics	August 2012
FDA Label: Marqibo Disease/s that Drug Treats:Ph- acute lymphoblastic leukemia Indications and Usage: ¹⁸ Marqibo is a vinca alkaloid indicated for the treatment of adult patients withPhiladelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)in second or greater relapse or whose disease has progressed following two ormore anti-leukemia therapies. This indication is based on overall responserate. Clinical benefit such as improvement in overall survival has not beenverified (1.1). DrugBank Targets: ¹⁶ 1. Tubulin beta chain;2. Tubulin alpha-4A chain Mechanism of Action: ¹⁸ Target: tubulin Action: alters polymerization equilibrium FDA: Marqibo is a sphingomyelin/cholesterol liposome-encapsulated formulation of vincristine sulfate.Non-liposomal vincristine sulfate binds to tubulin, altering the tubulin polymerization equilibrium, resulting inaltered microtubule structure and function. Non-liposomal vincristine sulfate stabilizes the spindle apparatus,preventing chromosome segregation, triggering metaphase arrest and inhibition of mitosis.

Drugs for Acute Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 360)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Arsenic trioxide

Approved, Investigational

Phase 4,Phase 2,Not Applicable

1327-53-3

518740

Amphotericin B

Approved, Investigational

Phase 4,Phase 3,Phase 2

1397-89-3

14956 5280965

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

22916-47-8

4189

Busulfan

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

55-98-1

2478

Cytarabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

147-94-4

6253

Fludarabine

Approved

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

21679-14-1, 75607-67-9

30751

Lenograstim

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

135968-09-1

Vidarabine

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

24356-66-9

32326 21704

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

50-18-0, 6055-19-2

2907

Mycophenolate mofetil

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

128794-94-5

5281078

Mycophenolic acid

Approved

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

24280-93-1

446541

Micafungin

Approved, Investigational

Phase 4,Phase 2

235114-32-6

3081921 477468

Posaconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 2

171228-49-2

147912

Anti-Bacterial Agents

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Antifungal Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Anti-Infective Agents

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

Antiparasitic Agents

Phase 4,Phase 3,Phase 2

Antiprotozoal Agents

Phase 4,Phase 3,Phase 2

Cytochrome P-450 CYP2C9 Inhibitors

Phase 4,Phase 3,Not Applicable

Cytochrome P-450 CYP3A Inhibitors

Phase 4,Phase 3,Not Applicable

Cytochrome P-450 Enzyme Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Hormone Antagonists

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Hormones

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Liposomal amphotericin B

Phase 4,Phase 3,Phase 2

Steroid Synthesis Inhibitors

Phase 4,Phase 3,Phase 2,Not Applicable

Adjuvants, Immunologic

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Alkylating Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Antimetabolites

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Antimetabolites, Antineoplastic

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Antineoplastic Agents, Alkylating

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Antiviral Agents

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

Immunosuppressive Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Antilymphocyte Serum

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Cyclosporins

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antirheumatic Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Echinocandins

Phase 4,Phase 2,Phase 1

Voriconazole

Approved, Investigational

Phase 3

137234-62-9

71616

Oprelvekin

Approved, Investigational

Phase 2, Phase 3

145941-26-0

Azacitidine

Approved, Investigational

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

320-67-2

9444

Decitabine

Approved, Investigational

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

2353-33-5

451668

Clofarabine

Approved, Investigational

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

123318-82-1

119182

Etoposide

Approved

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

33419-42-0

36462

Methylprednisolone

Approved, Vet_approved

Phase 3,Phase 1,Phase 2,Not Applicable

83-43-2

6741

Prednisolone

Approved, Vet_approved

Phase 3,Phase 1,Phase 2,Not Applicable

50-24-8

5755

Thiotepa

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

52-24-4

5453

Daunorubicin

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

20830-81-3

30323

Hydrocortisone

Approved, Vet_approved

Phase 3,Phase 2,Phase 1,Not Applicable

50-23-7

5754

Levoleucovorin

Approved, Investigational

Phase 3,Phase 2,Not Applicable

68538-85-2

Methotrexate

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

1959-05-2, 59-05-2

126941

Interventional clinical trials:

(show top 50) (show all 474)

#	Name	Status	NCT ID	Phase	Drugs
1	Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic	Unknown status	NCT00196768	Phase 4	Arsenic trioxide;Trisenox
2	PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia	Completed	NCT00362544	Phase 4	Ambisome
3	Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome	Completed	NCT01200355	Phase 4	micafungin;posaconazole
4	Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)	Completed	NCT00504764	Phase 4	Arsenic Trioxide;ATRA
5	Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation	Not yet recruiting	NCT02784561	Phase 4	Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG（Sanofi/Genzyme）
6	A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT	Not yet recruiting	NCT03190733	Phase 4	ATG
7	Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)	Not yet recruiting	NCT01339988	Phase 4	Busulfan/Cyclophosphamide
8	ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia	Terminated	NCT00386997	Phase 4	liposomal amphotericin B (AmBisome®)
9	Antifungal Prophylaxis in Pediatric Acute Leukemia	Unknown status	NCT00624143	Phase 3	ORAL VORICONAZOLE and IV Amphotericin B
10	A Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in the Young With Acute Leukemia Remission	Unknown status	NCT01067300	Phase 3
11	Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia	Unknown status	NCT02241031	Phase 2, Phase 3	thrombopoietin (TPO) and interleukin-11
12	Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome	Unknown status	NCT01809392	Phase 2, Phase 3	decitabine
13	Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation	Unknown status	NCT01800643	Phase 2, Phase 3
14	Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation	Unknown status	NCT01217723	Phase 3
15	Clove In The Treatment Of Relapsed Or Resistant Acute Leukemia In Children	Completed	NCT01385891	Phase 2, Phase 3	Clofarabine VP 16 ciclophospahamide
16	Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation	Completed	NCT01371656	Phase 3	levofloxacin
17	Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia	Completed	NCT00678275	Phase 3	ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
18	Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission	Completed	NCT00002534	Phase 3	cyclophosphamide;cytarabine;methylprednisolone;thiotepa
19	Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation	Completed	NCT01020175	Phase 3
20	Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen	Completed	NCT00774280	Phase 3	BuCy vs BuFlu
21	Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia	Completed	NCT00002700	Phase 3	asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;mitoxantrone hydrochloride;prednisolone;prednisone;therapeutic hydrocortisone;vincristine sulfate
22	Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2	Completed	NCT00931138	Phase 3	chemotherapy (Aracytine + Daunorubicin);chemotherapy (Aracytine + Daunorubicin);chemotherapy (Aracytine + Daunorubicin)
23	A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old	Completed	NCT00927498	Phase 3	conventional chemotherapy (AraC + Daunorubicin),;Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
24	Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)	Completed	NCT00880243	Phase 3	GM-CSF
25	A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients	Completed	NCT00163722	Phase 3
26	Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)	Completed	NCT00093990	Phase 3	Tipifarnib;Zarnestra; R115777
27	Timed-Sequential Induction in CBF-AML	Completed	NCT00428558	Phase 3	Chemotherapy (DAUNORUBICINE-CYTARABINE);Chemotherapy (DAUNORUBICINE-CYTARABINE)
28	Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia	Completed	NCT00046683	Phase 3	alemtuzumab
29	Prevention of Left Ventricular Dysfunction During Chemotherapy	Completed	NCT01110824	Phase 3	Enalapril and carvedilol
30	TK008: Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia	Recruiting	NCT00914628	Phase 3
31	Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)	Recruiting	NCT03016130	Phase 3
32	Transfusion Strategy in Hematological Intensive Care Unit	Recruiting	NCT02461264	Phase 3	Single red blood packed cells Transfusion;Two packed red blood cells Transfusion
33	Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)	Recruiting	NCT02345850	Phase 3	Cyclophosphamide;Tacrolimus;Methotrexate
34	MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT	Recruiting	NCT02673008	Phase 2, Phase 3
35	Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients	Recruiting	NCT02730299	Phase 3	NiCord®
36	The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line	Recruiting	NCT02962388	Phase 2, Phase 3	Anagrelide;Ruxolitinib (JAKAVI®);IFNα/ PegIFNα
37	Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.	Recruiting	NCT02038036	Phase 3	Best Available Therapy;ruxolitinib
38	Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients	Active, not recruiting	NCT01516580	Phase 3	Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
39	Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia	Active, not recruiting	NCT02085408	Phase 3	clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
40	Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome	Active, not recruiting	NCT01243476	Phase 3	Lenalidomide
41	Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)	Terminated	NCT00038805	Phase 2, Phase 3	Mylotarg
42	A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia.	Terminated	NCT00363025	Phase 3	Idarubicin versus daunorubicin
43	Stem Cell Transplantation for Hematological Malignancies	Terminated	NCT00176839	Phase 2, Phase 3	Busulfan;Cyclophosphamide;Melphalan;G-CSF;ATG
44	Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia	Terminated	NCT02785900	Phase 3	33A;placebo;azacitidine;decitabine
45	HCT Versus CT in Elderly AML	Terminated	NCT00766779	Phase 3	Non-Transplant treatment approach for consolidation
46	Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia	Withdrawn	NCT00943709	Phase 3	therapeutic insulin
47	ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)	Withdrawn	NCT01067274	Phase 3	Vesanoid (ATRA);AZACITIDINE (VIDAZA);CYTARABINE
48	Pilot Study of Hematopoietic Stem Cell Transplantation From Two Matched Sibling Donors in Treating Patients With Poor Prognosis Acute Leukemia and Advanced Lymphoproliferative Malignancies	Unknown status	NCT01385072	Phase 1, Phase 2
49	Pharmacokinetic Study of Busulfan in Allogeneic Stem Cell Transplantation in Adult Patients With Acute Leukemia	Unknown status	NCT01498016	Phase 2	Busulfan
50	Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT	Unknown status	NCT01956630	Phase 1, Phase 2

Search NIH Clinical Center for Acute Leukemia

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Acute Leukemia cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Acute Leukemia:

Promostem

Sources

Genetic Tests for Acute Leukemia

Genetic tests related to Acute Leukemia:

#	Genetic test	Affiliating Genes
1	Acute Leukemia ²⁹

Sources

Anatomical Context for Acute Leukemia

MalaCards organs/tissues related to Acute Leukemia:

⁴¹

Myeloid, Bone, Bone Marrow, T Cells, B Cells, Nk Cells, Liver

Sources

Publications for Acute Leukemia

Articles related to Acute Leukemia:

(show top 50) (show all 1963)

#	Title	Authors	Year
1	Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression. ( 29951132 )	Shah K....Kazi J.U.	2018
2	A greater birthweight increases the risk of acute leukemias in Mexican children-experience from the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia (MIGICCL). ( 29533016 )	JimAcnez-HernA!ndez E....MejA-a-ArangurAc J.M.	2018
3	Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. ( 29330396 )	Cesaro S....Styczynski J.	2018
4	Association between (GT)n Repeats in Heme Oxygenase-1 Gene Promoter and 3-Year Survival of Patients with Acute Leukemia: a Controlled, Cross-Sectional Study. ( 29951178 )	Kazemi M....Behjati M.	2018
5	Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. ( 29330391 )	Devillier R....Mohty M.	2018
6	Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. ( 29953464 )	Garcia-Vidal C....Soriano A.	2018
7	Maternal Exposure to Pesticides, Paternal Occupation in the Army/Police Force, and CYP2D6*4 Polymorphism in the Etiology of Childhood Acute Leukemia. ( 29432309 )	Ferri G.M....Santoro N.	2018
8	Re-induction chemotherapy using FLAG-mitoxantrone for adult patients with relapsed acute leukemia: a single-center experience from United Arab Emirates. ( 29951735 )	Hassan I.B....Alam A.	2018
9	Determination of CEBPA mutations by next generation sequencing in pediatric acute leukemia. ( 29947237 )	Akin D.F....Akar N.	2018
10	Fibroblast Growth Factor 23-Induced Hypophosphatemia in Acute Leukemia. ( 29696242 )	Reinert R.B....Koenig R.J.	2018
11	Relatively favorable prognosis for MLL-rearranged childhood acute leukemia with reciprocal translocations. ( 29943896 )	Yang L....Chen J.	2018
12	Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. ( 29247780 )	Shimoni A....Nagler A.	2018
13	Salvaged allogeneic hematopoietic stem cell transplantation for pediatric chemotherapy refractory acute leukemia. ( 29423036 )	Wang J....Zhang W.	2018
14	Prevalence and Predictors of Invasive Fungal Infections in Children with Persistent Febrile Neutropenia Treated for Acute Leukemia - A Prospective Study. ( 29956075 )	Kumar J....Kabra S.K.	2018
15	Flow cytometric characterization of acute leukemia reveals a distinctive &quot;blast gate&quot; of murine T-lymphoblastic leukemia/lymphoma. ( 29416774 )	Pan Z....Li Z.	2018
16	The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia. ( 29899571 )	Hochberg J....Cairo M.S.	2018
17	Hyperleukocytosis in infant acute leukemia: a role for manual exchange transfusion for leukoreduction. ( 29399859 )	Runco D.V....Fasano R.M.	2018
18	Clinical significance of the TNF-I+ receptors, TNFRSF2 and TNFRSF9, on cell migration molecules Fascin-1 and Versican in acute leukemia. ( 29861382 )	El Kramani N....Al-Gayyar M.M.H.	2018
19	Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. ( 29449681 )	Kurt H....Hu S.	2018
20	Congestive heart failure among children with acute leukemia: a population-based matched cohort study. ( 29966479 )	Chellapandian D....Sung L.	2018
21	Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. ( 29981272 )	Gilleece M.H....Nagler A.	2018
22	VEGF signaling in acute leukemia: mitochondrial connections. ( 29854867 )	NA^brega-Pereira S....Dias S.	2018
23	Clinicohematological Profile of Febrile Neutropenia in Childhood Acute Leukemia and Utility of Serum Procalcitonin Levels in Neutropenic Patients. ( 29910543 )	Kapoor R....Agarwal P.	2018
24	Secondary Acute Leukemia in Sarcoma Patients: A Population-Based Study. ( 29413281 )	Sanford N.N....Chen Y.L.	2018
25	Stodtmeister Cells (Polymorphs with Pelger-HuA<t Anomaly) Showing &quot;Faggots&quot; in Mixed Phenotypic Acute Leukemia (T/Myeloid). ( 29398816 )	Sehgal T....Kaul E.	2018
26	Derepression of the Iroquois Homeodomain Transcription Factor Gene IRX3 Confers Differentiation Block in Acute Leukemia. ( 29346763 )	Somerville T.D.D....Somervaille T.C.P.	2018
27	Moxifloxacin versus levofloxacin for antibacterial prophylaxis in acute leukemia patients. ( 29310512 )	Lee P....Pettit N.N.	2018
28	Novel biallelic ATM mutations coexist with a mosaic form of triple X syndrome in an 11-year-old girl at remission after T cell acute leukemia. ( 29492593 )	Sharapova S.O....Aleinikova O.V.	2018
29	Oral health status in adult patients with newly diagnosed acute leukemia. ( 28536781 )	Busjan R....Ziebolz D.	2018
30	Mometasone furoate inhibits growth of acute leukemia cells in childhood by regulating PI3K signaling pathway. ( 29421985 )	Wang X....Gong D.	2018
31	Clinical and Genomic Characterization of Recurrent Enterococcal Bloodstream Infection in Patients With Acute Leukemia. ( 29977964 )	Messina J.A....Sung A.D.	2018
32	Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients with intensive chemotherapy. ( 29880612 )	Brunel A.S....Bochud P.Y.	2018
33	Anti-D Alloimmunization after RhD-Positive Platelet Transfusion in RhD-Negative Women under 55 Years Diagnosed with Acute Leukemia: Results of a Retrospective Study. ( 29928170 )	Villalba A....Solves P.	2018
34	Chronic disseminated candidiasis and acute leukemia: Impact on survival and hematopoietic stem cell transplantation agenda. ( 29307444 )	Grateau A....Ader F.	2018
35	Single Dose Daily Fractionated Is Not Inferior To Twice A Day Fractionated Total Body Irradiation Prior To Allogeneic Stem Cell Transplantation For Acute Leukemia: A Useful Practice Simplification Resulting From The Sarasin Study. ( 29928948 )	Belkacemi Y....Nagler A.	2018
36	Diagnostic Dilemma in Ambiguous Lineage Acute Leukemia: A Case Report. ( 29398827 )	Singh N....Mehta A.	2018
37	Acute bilateral retina hemorrhages beneath internal limiting membrane: An unusual ophthalmological case report of acute leukemia during complete clinical remission. ( 29443727 )	Lyu S....Gao Y.	2018
38	Targeting the bone marrow microenvironment in acute leukemia. ( 29431560 )	Karantanou C....Krause D.S.	2018
39	Hematopoietic cell transplantation for myeloid/NK cell precursor acute leukemia in second remission. ( 29881556 )	Noguchi Y....Takagi M.	2018
40	Clinical Outcome, Healthcare Cost and Length of Hospital Stay Among Patients With Bloodstream Infections and Acute Leukemia in a Cancer Center in Eastern India. ( 29909820 )	Muennichow C.E....Bhattacharya S.	2018
41	Clinical significance of HLA-E genotype and surface/soluble expression levels between healthy individuals and patients with acute leukemia. ( 29969046 )	Xu Y.P....Hong W.X.	2018
42	Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients. ( 29334284 )	Cosimato V....Del Vecchio L.	2018
43	A protocol to isolate and qualify purified human preantral follicles in cases of acute leukemia, for future clinical applications. ( 29304838 )	Mouloungui E....Amiot C.	2018
44	Acute Leukemia is Associated with Cardiac Alterations before Chemotherapy. ( 28927558 )	Assuncao B.M.B.L....Scherrer-Crosbie M.	2017
45	Genomic characterization of chromosome translocations in patients with T/myeloid mixed-phenotype acute leukemia. ( 28882084 )	Pallavajjala A....Ning Y.	2017
46	Bone Marrow Necrosis in Newly Diagnosed Acute Leukemia: Two Case Reports and Review of the Literature. ( 28680961 )	Quintela A....Plesa A.	2017
47	Lymphocyte recovery is an independent predictor of relapse in allogeneic hematopoietic cell transplantation recipients for acute leukemia. ( 28900606 )	Damlaj M....Alaskar A.	2017
48	Typhlitis (neutropenic enterocolitis) in patients with acute leukemia: a review. ( 28075196 )	Portugal R....Nucci M.	2017
49	Risk factors in patients undergoing haploidentical hematopoietic stem cell transplantation for high-risk childhood acute leukemia. ( 28825215 )	Han D.M....Wang H.X.	2017
50	Leukemic phase of hepatosplenic T-cell lymphoma: A great masquerader of acute leukemia. ( 28937394 )	Sharma S....Varma N.	2017

Sources

Genes for Acute Leukemia

Genes related to Acute Leukemia (0 elite genes):

(show all 30)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	BAALC	BAALC, MAP3K1 And KLF4 Binding	Protein Coding	50.92	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name Proteins Transcripts (show sections)
2	MTHFR	Methylenetetrahydrofolate Reductase	Protein Coding	44.65	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Summaries Proteins (show sections)	17071478 17071465 11340609 (more) 11274424 20367562 12827651 17339179 12672676
3	FLT3	Fms Related Tyrosine Kinase 3	Protein Coding	43.16	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications (show sections)	17584026 15778081 17387224 (more) 18925699 20302766 20515557 12357354 15996732 17233551 19052976 8677746 20072157 1384791 10803532 16757428 12796379 16800917 16321848 16185475 10373018 19075657 16557239 12836614 15374944 16025155 15618475 8562934 20425341 17708815 17943971 8637232 20370649 15950498 18977066 15150124 16418499 17584149
4	RUNX1	Runt Related Transcription Factor 1	Protein Coding	43.1	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications (show sections)	17920312 16575471 20306249 (more) 17532767 17968322 8613429 10482986 17011991 19151769 10684580 20080465 20007546 10717473 12771199 15156187 15950498 16247465 20181616 8395311 8049440 12604126 15988004 16803898 11566347 12555067 11328817 10594034 19357396 18224409 7780155 9031072 10825008 11023523
5	WT1	Wilms Tumor 1	Protein Coding	41.61	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Functions (show sections)	7949179 10100271 16129044 (more) 7596170 17803653 19212333 19662212 10480287 18161786 12215007 12835718 14510942 16876863 10422290 10921096 12357365 15363132 9222290 15730716 9484784 19811333 7643450 15534117 8639907 8630376 17690705 15907324 12080641 10529509 9531607 16341043 16471322 12971856 12200377 11807803 8943879 20129107 15339675 12411055 12215009 10607714 9609529 9052749 15920488 11852808 11296223 20013787 19404640 18443273 12837194 12613515 11602325 10378895 15223632 11014901 12750711 9001425 10674900 20435628 10360378
6	ETV6	ETS Variant 6	Protein Coding	39.79	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications (show sections)	11343784 8808688 12823350 (more) 7780150 9529134 12555218 9060558 11439334
7	KIT	KIT Proto-Oncogene Receptor Tyrosine Kinase	Protein Coding	39.32	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications (show sections)	9407735 9658721 10229319 (more) 10739002 8605274 12562262 18977066 12836614 20165856 7529077 1371882 18787634 8127154 12194988 18337231
8	JAK2	Janus Kinase 2	Protein Coding	38.98	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications (show sections)	18394555 18618714 15805263 (more) 16037387 16557239 18297515 17077140 17068151 18024602 18230964 19489438
9	KMT2A	Lysine Methyltransferase 2A	Protein Coding	36.39	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	8443374 11069023 8824725 (more) 9447829 17284365 9029018 10557043 12472570 7658717 16983345 9230194 11167824 8016145 16383239 7529550 1423625 7885037 15755504 15160920 9010221 8703835 8298125 8378328 15269783 8709635 9247308 20206559 9539779 12957285 19074864 8329709 8616868 9353299 15323147 15322560 12860012 11522623 11510203 11433529 11289128 10583275 9760153 18224408 16433901 15626757 14575001 11527155 11477655 10822761 9844603 9539705 9292512 8558942 7675546 19262598 18474298 17164354 16511515 16843108 16085566 8134107 8282816 8361504 17854664 17726105 16857431 16105754 15464450 12368154 12165445 10679814 10457404 10381524 9592986 10825008 10706136 10374852 8108133 19277575 17942707 16357144 16424875 15815718 12835743 10233389 8616778 8044771 8506328 20139053 19530238 8934551 8640793 7761425 7949133 20080465 17957188 17854671 16158928 14704031
10	STMN1	Stathmin 1	Protein Coding	36.08	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Expressions (show sections)	1917919 1401087 8412315 (more) 9324290 7925472 1930203 8125092
11	CEBPA	CCAAT Enhancer Binding Protein Alpha	Protein Coding	35.87	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications (show sections)	12351377
12	CREBBP	CREB Binding Protein	Protein Coding	34.14	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Functions (show sections)	10469454 10706136
13	ANPEP	Alanyl Aminopeptidase, Membrane	Protein Coding	33.56	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	12562262 11241503 8023515 (more) 1493908 10229319 8624374
14	MPO	Myeloperoxidase	Protein Coding	33.38	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	19935430 9725460 8396697 (more) 17479404 8386105 7493141 1666891 9217186 8579056 15624329 9704614 1311196 1333591 7719239 10233410 10986389 12562262 15786701 9140287 2173803 19327122 19298796 8167554 7944272 8035623 8023515 8118606 8220154 7962655 10655992 8624374 9859768 7496347 8291896 8388970 8383541 10889907 8155836 1977771 8853033 12513830 11340609 10359066 9766845 9479874 8659452 8237269 8501986 16298822 16893519 17325954 19605811 19893347 1913454 1331562
15	GSTM1	Glutathione S-Transferase Mu 1	Protein Coding	33.22	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Functions (show sections)	15862746 17581325 18610829 (more) 16676594 15738600 16493615 12827651
16	MLLT1	MLLT1, Super Elongation Complex Subunit	Protein Coding	32.45	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	16990786
17	AFF1	AF4/FMR2 Family Member 1	Protein Coding	24.74	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	8353274 7698025 11527155 (more) 8378328 1423625 15269783
18	CSF3	Colony Stimulating Factor 3	Protein Coding	23.77	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	8691565 7531394 16858272 (more) 1714757 10942233 9644302 10897214 8637222 11290617 10731945 12752636 9590144 18020493 8624474 9387641 7689127 8588087 10217192 10358698 11869937 8528046 1534271 1709294 19379589 16928319 17563736 16988532 11979751 11486703 8721901 19749982 16777623 11736947 11399510 11105617 11091203 9570678 8656684 19848320 17128529 1697646 17631182 16192477 10657885 7535728 7526087 1372766 1707827 15850828 15461640 14691124 11293503 16295383 14959860 9447843 8608239 7525188 7525857 16080844 8616084 17526862 12393493 14675405 14642178
19	DNTT	DNA Nucleotidylexotransferase	Protein Coding	23.06	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	7723388 1338518 18426728 (more) 7524307 10233410 11131924 19687594 7639197 10655992 7962655 8853033 7496347 1299244 15205205 7654005 8220154 1913454
20	CD34	CD34 Molecule	Protein Coding	22.55	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	19454497 9001869 1712541 (more) 7505888 7526089 10916777 8635059 9658721 11489469
21	MLLT3	MLLT3, Super Elongation Complex Subunit	Protein Coding	22.43	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	15269783
22	PAX5	Paired Box 5	Protein Coding	22.41	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications (show sections)	14676435 15492262
23	CD33	CD33 Molecule	Protein Coding	22.27	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	11328295
24	MLLT10	MLLT10, Histone Lysine Methyltransferase DOT1L Cofactor	Protein Coding	22.24	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	11423977
25	TCF3	Transcription Factor 3	Protein Coding	21.93	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries (show sections)
26	ZNF384	Zinc Finger Protein 384	Protein Coding	21.84	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries (show sections)
27	ABCB1	ATP Binding Cassette Subfamily B Member 1	Protein Coding	21.81	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	8477061 16086884 15512810 (more) 17538395 16614510 10897123 9150348 1380280 9886170 1859877 11877057 7694687 19291917 9742628 10444168 12917035 8731823 12028995 9439046 10920991 8556928 1283551 19862976 9408959 7808005 14526424 8704189 1974821 16138358 15266171 9479874 8535665 7536492 8639853 10971394 10500792 10500786 10500776 10198619 8726405 8656697 8574159 7727868 16109615 12960118 11036680 7895588 7993790 19635183 17301357 11798628 11197207 7622426 8102639 8630412 7528566 7914424 8100604 16799654 15014037 11697502 9868094 1353871 17493328 15854288 9772402 8118816 15363121 8097038 7896208 8075575 9110459 10374270
28	TAL1	TAL BHLH Transcription Factor 1, Erythroid Differentiation Factor	Protein Coding	21.62	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	10049045 1311214 15917481 (more) 8142619 9211539 18495761 16298389 8058326
29	IL3	Interleukin 3	Protein Coding	21.55	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	1766257 8624474 9891868 (more) 2403822 2323674 2090254 7689127 2048564 1635377 8449858 14752873 10721770 2312610 8881103 7515617 8422455 9414269 9067570 8211215 9466481 10496036
30	CD7	CD7 Molecule	Protein Coding	21.21	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	1701841

Sources

Variations for Acute Leukemia

Sources

Expression for Acute Leukemia

Search GEO for disease gene expression data for Acute Leukemia.

Sources

Pathways for Acute Leukemia

Pathways related to Acute Leukemia according to GeneCards Suite gene sharing:

(show all 12)

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.66	CEBPA CREBBP FLT3 KIT MPO RUNX1
2	Pathways in cancer ³⁷	12.59	CEBPA CREBBP FLT3 GSTM1 JAK2 KIT
3	NF-kappaB Signaling ⁴	12.36	CD34 CEBPA JAK2 KIT MPO RUNX1
4	Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁵	11.8	ANPEP CD34 CSF3 FLT3 KIT MPO
5	Hematopoietic cell lineage ³⁷	11.62	ANPEP CD34 CSF3 DNTT FLT3 KIT
6	Innate Lymphoid Cell Differentiation Pathways ⁶⁵	11.59	CD34 KIT RUNX1
7	Transcriptional misregulation in cancer ³⁷	11.55	AFF1 CEBPA ETV6 FLT3 KMT2A MLLT1
8	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.54	CD34 FLT3 KIT
9	C-MYB transcription factor network ¹	11.39	ANPEP CD34 CEBPA CREBBP GSTM1 KIT
10	B Cell Development Pathways ⁶⁵	11.36	CD34 FLT3 KIT
11	Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex ¹	10.92	CREBBP ETV6 FLT3
12	Benzene metabolism ¹	10.26	GSTM1 MPO

Sources

GO Terms for Acute Leukemia

Cellular components related to Acute Leukemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytosol	GO:0005829	9.4	BAALC DNTT ETV6 FLT3 GSTM1 JAK2

Biological processes related to Acute Leukemia according to GeneCards Suite gene sharing:

(show all 15)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription, DNA-templated	GO:0045893	9.95	CEBPA CREBBP KMT2A RUNX1 WT1
2	positive regulation of transcription by RNA polymerase II	GO:0045944	9.95	CEBPA CREBBP CSF3 ETV6 KMT2A RUNX1
3	transcription by RNA polymerase II	GO:0006366	9.8	CEBPA ETV6 KMT2A MLLT1 RUNX1 WT1
4	positive regulation of DNA binding transcription factor activity	GO:0051091	9.7	CSF3 JAK2 KIT
5	cytokine-mediated signaling pathway	GO:0019221	9.65	CEBPA CSF3 FLT3 JAK2 KIT
6	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.61	FLT3 JAK2 KIT
7	macrophage differentiation	GO:0030225	9.51	CEBPA CSF3
8	embryonic hemopoiesis	GO:0035162	9.49	KIT KMT2A
9	regulation of myeloid cell differentiation	GO:0045637	9.48	CREBBP RUNX1
10	granulocyte differentiation	GO:0030851	9.46	CEBPA CSF3
11	hemopoiesis	GO:0030097	9.46	CD34 FLT3 KIT RUNX1
12	myeloid progenitor cell differentiation	GO:0002318	9.37	FLT3 KIT
13	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	9.26	CSF3 FLT3 JAK2 KIT
14	hematopoietic stem cell proliferation	GO:0071425	8.8	CD34 ETV6 RUNX1
15	cell differentiation	GO:0030154	10.01	ANPEP ETV6 FLT3 JAK2 KIT STMN1

Molecular functions related to Acute Leukemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	transcription regulatory region DNA binding	GO:0044212	9.26	CEBPA KMT2A RUNX1 WT1
2	DNA binding transcription factor activity	GO:0003700	9.17	AFF1 CEBPA CREBBP ETV6 KMT2A RUNX1

Sources

Sources for Acute Leukemia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia